Sigachi Industries Ltd

Sigachi Industries will hold a meeting of the Board of Directors of the Company on 8 February 2025.Powered by Capital Market - Live

Sigachi Industries is establishing a state-of-the-art R&D Center in Hyderabad to enhance its Research and Development (R&D) capabilities. This strategic initiative involves an investment of up to USD 1 million with the objective of bringing its critical API developments and Analytical Efforts under one roof. Powered by Capital Market - Live

Revenue from operations grew by 25.66% to Rs 139.41 crore in Q3 FY25 from Rs 110.94 crore registered in Q3 FY24. Profit before tax stood at Rs 26.70 crore in Q3 FY25, 35.94% higher than Rs 19.64 crore recorded in the same period last year. Total expenses rallied 23.34% to Rs 114.72 crore in Q3 FY25 as compared to Rs 93.01 crore reported in Q3 FY24. The cost of materials consumed stood at Rs 59.55 crore (up 63.15% YoY), and employee benefit expenses were at Rs 19.46 crore (up 39% YoY) during the period under review. On a nine-month basis, the company's net profit added 33.57% to Rs 56.29 crore in 9M FY25 as against to Rs 42.14 crore posted in 9M FY24. Revenue from operations increased 25.66% YoY to Rs 139.41 crore in 9M FY25. Meanwhile, the company's board approved the appointment of Amit Raj Sinha, MD & chief executive officer of the company, as chairman of the board of the company. Telangana-based Sigachi Industries is engaged in the manufacturing of microcrystalline cellulose (MCC), which is widely used in the pharmaceutical, food, beverage, cosmetic, and paint industries. The most common uses of MCC are in vitamin supplements and tablets. It also acts as a bulking agent in food production. MCC is produced from refined wood pulp, which is imported by the company. Powered by Capital Market - Live

Net profit of Sigachi Industries rose 32.53% to Rs 21.35 crore in the quarter ended December 2024 as against Rs 16.11 crore during the previous quarter ended December 2023. Sales rose 25.66% to Rs 139.42 crore in the quarter ended December 2024 as against Rs 110.95 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales139.42110.95 26 OPM %23.7920.36 - PBDT31.3722.46 40 PBT26.7119.64 36 NP21.3516.11 33 Powered by Capital Market - Live

Sigachi Industries will hold a meeting of the Board of Directors of the Company on 18 January 2025.Powered by Capital Market - Live

Sigachi Industries has received reaffirmation in credit rating for bank facilities at CARE A-; Stable/ CARE A2. Powered by Capital Market - Live

Achieving the Certificate of Suitability (CEP) for this API will enable the company to export this product in Europe and other CEP accepting countries. Propafenone Hydrochloride, widely used in the treatment of cardiac arrhythmias, is a high demand API with a current global market size of $1.2 billion. 'The market is poised for robust growth, with projections reaching $ 2.1 billion by 2032, reflecting a CAGR of 7% over the forecast period. This growth is driven by the increasing prevalence of cardiovascular diseases, growing adoption of generic medications, and rising healthcare expenditure globally,' the company stated in regulatory filing. Amit Raj Sinha, managing director and CEO of Sigachi Industries, said, 'The submission of our first CEP filing is a testament to Trimax Biosciences' commitment to quality, compliance, and innovation in the API domain. This achievement not only strengthens our position in the pharmaceutical supply chain but also aligns with our vision of providing reliable and sustainable pharmaceutical solutions on a global scale.' Telangana based Sigachi Industries is engaged in manufacturing of microcrystalline cellulose (MCC), which is widely used in pharmaceutical, food, beverage, cosmetic and paint industry. The most common uses of MCC are in vitamin supplements and tablets. It also acts as a bulking agent in food production. MCC is produced from refined wood pulp which is imported by the company. The company's consolidated net profit jumped 43.8% to Rs 21.78 crore on 25.9% increase in net sales to Rs 124.90 crore in Q2 FY25 over Q2 FY24.Powered by Capital Market - Live

Sigachi Industries announced about its recent submission of CEP filing for 'Propafenone Hydrochloride'. This is a significant step towards ensuring European regulatory standards and highest levels of product quality and safety. It will also strategically diversify Sigachi's revenue channels to enhance greater value for all stakeholders involved Propafenone Hydrochlride, widely used in the treatment of cardiac arrhythmias, is a highdemand API with a current global market size of USD 1.2 billion. Powered by Capital Market - Live

Sigachi Industries announced the resignation of Sarweswara Reddy Sanivarapu (DIN: 00459605) as Chairman of the Board and Independent Director of the Company on 25 November 2024. Powered by Capital Market - Live

Net profit of Sigachi Industries rose 43.76% to Rs 21.78 crore in the quarter ended September 2024 as against Rs 15.15 crore during the previous quarter ended September 2023. Sales rose 25.93% to Rs 124.90 crore in the quarter ended September 2024 as against Rs 99.18 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales124.9099.18 26 OPM %13.7921.59 - PBDT29.7720.74 44 PBT26.5518.21 46 NP21.7815.15 44 Powered by Capital Market - Live